---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-116468"
form_type: "8-K"
ticker: "TELA"
cik: "0001561921"
company_name: "TELA Bio, Inc."
filed_at: "2022-11-09T23:59:59+00:00"
generated_at: "2026-06-22T01:13:37.101560+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# TELA Bio Q3 revenue $11.2M (+46% YoY); reaffirms FY2022 guidance $42-45M

## Summary
- Q3 revenue $11.2M, up 46% YoY; gross margin 66% vs 60% a year ago.
- Net loss $10.7M vs $8.3M; operating loss $9.5M vs $7.2M in Q3 2021.
- Reaffirmed FY2022 revenue guidance $42-45M (43-53% growth over FY2021).
- OviTex revenue +29% YoY, OviTex PRS +108% YoY; BRAVO study shows 2.6% recurrence rate.
- Closed August oversubscribed public offering netting $34.4M; cash $54.2M at quarter end.

## SEC filing metadata
- accession: 0001104659-22-116468
- form_type: 8-K
- ticker: TELA
- cik: 0001561921
- company_name: TELA Bio, Inc.
- filed_at: 2022-11-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1561921/000110465922116468/0001104659-22-116468-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1561921/000110465922116468/tm2230071d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-116468
- JSON: https://secwatch.observer/filing/0001104659-22-116468.json
- Plain text: https://secwatch.observer/filing/0001104659-22-116468.txt

## Key facts
- Earnings Releases
  TELA Bio, Inc. reported the third quarter ended September 30, 2022 results: revenue $11.2 million, net income $10.7 million. Guidance reaffirmed.
  - Period: the third quarter ended September 30, 2022
  - Revenue: $11.2 million
  - Net income: $10.7 million
  - Guidance: reaffirmed
  - Result: reported results
  source text: and restoration of the patient's own anatomy, today reported financial results for the third quarter ended September 30, 2022. Recent Highlights · Reported revenue of $11.2 million for the third quarter, representing growth of 46% over the same quarter of 2021; · Increased demand for OviTex ® and OviTex PRS Reinforced Tissue Matrix products in the third
  evidence_url: https://www.sec.gov/Archives/edgar/data/1561921/000110465922116468/0001104659-22-116468-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.